BACKGROUND: Platelets are the major source of circulating sP-selectin. Elevated levels of this protein have been found in many atherothrombotic disorders. Thus, we investigated whether sP-selectin dosage might reflect platelet function in patients with risk factors for or with established cardiovascular diseases and whether its levels can be modulated by aspirin therapy. METHODS: Plasma sP-selectin levels and light transmission platelet aggregometry (LTA) were analyzed in 152 outpatients. The effects of a 6-month aspirin therapeutic course on sP-selectin levels and LTA in 51 consecutive patients have been also investigated. RESULTS: Significant correlations were observed between sP-selectin and Mx% LTA in response to epinephrine (p=0.022) and arachidonic acid (p=0.006), or between sP-selectin and collagen lag-phase (p=0.016). Multiple regression analysis showed that the only predictors of sP-selectin levels were platelet number (p<0.001) and collagen-induced lag-phase (p<0.01). Aspirin-treated patients showed a significant reduction of sP-selectin levels by 13% (p=0.021) which significantly correlated with collagen-induced lag-phase (p=0.005). CONCLUSIONS: sP-selectin dosage could be proposed as a reliable marker of platelet activation in patients with major atherosclerotic risk factors either in the absence of clinically overt disease, and might represent a valid tool to asses in vivo platelet behavior.
BACKGROUND: Platelets are the major source of circulating sP-selectin. Elevated levels of this protein have been found in many atherothrombotic disorders. Thus, we investigated whether sP-selectin dosage might reflect platelet function in patients with risk factors for or with established cardiovascular diseases and whether its levels can be modulated by aspirin therapy. METHODS: Plasma sP-selectin levels and light transmission platelet aggregometry (LTA) were analyzed in 152 outpatients. The effects of a 6-month aspirin therapeutic course on sP-selectin levels and LTA in 51 consecutive patients have been also investigated. RESULTS: Significant correlations were observed between sP-selectin and Mx% LTA in response to epinephrine (p=0.022) and arachidonic acid (p=0.006), or between sP-selectin and collagen lag-phase (p=0.016). Multiple regression analysis showed that the only predictors of sP-selectin levels were platelet number (p<0.001) and collagen-induced lag-phase (p<0.01). Aspirin-treated patients showed a significant reduction of sP-selectin levels by 13% (p=0.021) which significantly correlated with collagen-induced lag-phase (p=0.005). CONCLUSIONS:sP-selectin dosage could be proposed as a reliable marker of platelet activation in patients with major atherosclerotic risk factors either in the absence of clinically overt disease, and might represent a valid tool to asses in vivo platelet behavior.
Authors: Binita Shah; Jeffrey S Berger; Nicholas S Amoroso; Xingchen Mai; Jeffrey D Lorin; Ann Danoff; Arthur Z Schwartzbard; Iryna Lobach; Yu Guo; Frederick Feit; James Slater; Michael J Attubato; Steven P Sedlis Journal: Am J Cardiol Date: 2014-02-12 Impact factor: 2.778
Authors: Nino Gogitidze Joy; Maka S Hedrington; Vanessa J Briscoe; Donna B Tate; Andrew C Ertl; Stephen N Davis Journal: Diabetes Care Date: 2010-07 Impact factor: 17.152
Authors: Dorothee Kaudewitz; Philipp Skroblin; Lukas H Bender; Temo Barwari; Peter Willeit; Raimund Pechlaner; Nicholas P Sunderland; Karin Willeit; Allison C Morton; Paul C Armstrong; Melissa V Chan; Ruifang Lu; Xiaoke Yin; Filipe Gracio; Katarzyna Dudek; Sarah R Langley; Anna Zampetaki; Emanuele de Rinaldis; Shu Ye; Timothy D Warner; Alka Saxena; Stefan Kiechl; Robert F Storey; Manuel Mayr Journal: Circ Res Date: 2015-12-08 Impact factor: 17.367